Category News

Cosette Pharmaceuticals Expands Branded Portfolio with SYMPAZAN® and Other Asset Acquisition from Assertio

Cosette Pharmaceuticals Broadens Branded Portfolio with Acquisition of SYMPAZAN® and Additional Assets from Assertio Cosette Pharmaceuticals has announced the successful closing of a strategic acquisition that significantly expands its branded product portfolio and reinforces its position in key therapeutic areas.…

Read MoreCosette Pharmaceuticals Expands Branded Portfolio with SYMPAZAN® and Other Asset Acquisition from Assertio

Humana Inc. and CPESN USA Launch Value-Based Pharmacist Rewards Program to Enhance Chronic Care

Humana Inc. Healthy Horizons in Ohio and CPESN USA Introduce Value-Based Pharmacist Quality Rewards Program to Improve Chronic Disease Care Humana Inc., through its Medicaid plan Humana Healthy Horizons in Ohio, has announced an expanded collaboration with CPESN USA aimed…

Read MoreHumana Inc. and CPESN USA Launch Value-Based Pharmacist Rewards Program to Enhance Chronic Care

Cognito Therapeutics Partners with Initiative to Replace “Dementia” Terminology Across Communications

Cognito Therapeutics Collaborates with Initiative to Replace the “D-Word,” Committing to Remove “Dementia” from All Communications Cognito Therapeutics, a late clinical-stage neurotechnology company focused on developing non-invasive therapies for neurodegenerative diseases, has announced a new partnership with the Initiative to…

Read MoreCognito Therapeutics Partners with Initiative to Replace “Dementia” Terminology Across Communications

Acadia Pharmaceuticals Announces Broad U.S. Availability of DAYBUE STIX for the Treatment of Rett Syndrome

Acadia Pharmaceuticals Expands U.S. Access to DAYBUE STIX for Patients with Rett Syndrome Acadia Pharmaceuticals has announced that DAYBUE® STIX (trofinetide) for oral solution—a newly developed powder formulation of its Rett syndrome therapy—is now broadly available across the United States.…

Read MoreAcadia Pharmaceuticals Announces Broad U.S. Availability of DAYBUE STIX for the Treatment of Rett Syndrome

Affinia Therapeutics Secures Health Canada Approval to Launch Phase 1/2 UPBEAT Trial of AFTX-201 in BAG3-Related DCM

Affinia Therapeutics Secures Health Canada Clearance to Launch UPBEAT© Phase 1/2 Trial Evaluating AFTX-201 for BAG3-Related Dilated Cardiomyopathy Affinia Therapeutics, a clinical-stage biotechnology company focused on advancing next-generation gene therapies for serious cardiovascular diseases, has announced a key regulatory milestone…

Read MoreAffinia Therapeutics Secures Health Canada Approval to Launch Phase 1/2 UPBEAT Trial of AFTX-201 in BAG3-Related DCM

Armatus Unveils Breakthrough Data Advancing TVR110 MicroRNA Therapy for Charcot-Marie-Tooth Disease Type 1A

Armatus Reports Promising Breakthrough Data on TVR110, a Vectorized MicroRNA Therapy for Charcot-Marie-Tooth Disease Type 1A Armatus Bio, a late-preclinical biotechnology company focused on developing next-generation vectorized RNA interference (RNAi) therapies for neuromuscular disorders, has announced the publication of important…

Read MoreArmatus Unveils Breakthrough Data Advancing TVR110 MicroRNA Therapy for Charcot-Marie-Tooth Disease Type 1A

PharmaEssentia Enters Investment Agreement to Establish New Manufacturing Facility in Puerto Rico

PharmaEssentia Announces Investment Agreement to Build New Manufacturing Facility in Puerto Rico PharmaEssentia Corporation, a global biopharmaceutical company headquartered in Taiwan, has taken a significant step in expanding its international manufacturing footprint with the signing of an investment agreement for…

Read MorePharmaEssentia Enters Investment Agreement to Establish New Manufacturing Facility in Puerto Rico